Design Therapeutics, Inc. (DSGN) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 3 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for DSGN is $15.67, representing a +24.0% upside from the current price of $12.64. Price targets range from a low of $14.00 to a high of $18.00.
